Increasing combined resistance and carbapenem resistance in certain bacteria remain a concern, highlights the annual ECDC report with data on antimicrobial resistance in Europe.
Over the last four years, antimicrobial resistance in gram-negative bacteria, such as Escherichia coli and Klebsiella pneumoniae, is on the rise in many parts in Europe.
Of special concern is the increase in combined resistance to third-generation cephalosporins, fluoroquinolones and aminoglycosides, which has increased significantly both at EU/EEA level and in many of the Members States between 2012 and 2015.
The increase in combined resistance is worrying, as this leaves few treatment alternatives for patients suffering from infections caused by these bacteria. It may also lead to an increased use of carbapenems – a last-line group of antibiotics -, which contributes to the emergence of carbapenem-resistant bacteria.
Although the percentage of isolates resistant to carbapenems remained low in most EU/EEA countries in 2015, resistance to carbapenems increased significantly for K. pneumoniae at EU/EEA level between 2012 and 2015. A majority of the carbapenem-resistant isolates were also resistant to third-generation cephalosporins, fluoroquinolones and aminoglycosides, further complicating the choice for effective treatment.
The ECDC Annual report on Antimicrobial resistance surveillance in Europe
The ECDC annual report presents antimicrobial resistance data for seven microorganisms of major public health importance: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter species, Streptococcus pneumoniae, Staphylococcus aureus, and Enterococci. The report combines the antimicrobial resistance data reported to EARS-Net by 30 EU/EEA countries in 2016 (based on 2015 data), with trend analyses of data for the period 2012–2015.
Link to the report: Antimicrobial resistance surveillance in Europe, 2015 http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1637
QuikRead go® CRP
Test before prescribing
QuikRead go CRP is a fast and simple rapid test for quantitative determination of C-reactive protein (CRP) in whole blood, serum and plasma with the QuikRead go instrument. The test gives reliable results within minutes and speeds up the path to the right diagnosis. Accurate measurement of C-reactive protein (CRP) can be critical in the clinical management of a patient with symptoms of infection. Read more: QuikRead go CRP and QuikRead go CRP+Hb